Business Context and Reporting Period
Company: Icecure Medical Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Report Date: July 10, 2025
Reporting Period: Preliminary unaudited financial information for the three and six months ended June 30, 2025.
Key Financial Metrics
- Product Sales (3 months ended June 30, 2025): Approximately $525,000.
- Product Sales (6 months ended June 30, 2025): Approximately $1.25 million.
- Gross Profit and Margins: Expected to be significantly lower for the six months ended June 30, 2025, compared to the same period in 2024.
- Net Loss: Expected to be higher for the six months ended June 30, 2025, compared to the six months ended June 30, 2024.
- Operating Expenses: Estimated to not be materially affected by lower revenue, though fluctuations unrelated to revenue levels may occur.
- Cash Flow, Debt, and Liquidity: The filing text does not provide clear values for cash flow, debt levels, or specific liquidity metrics.
Material Changes Versus Prior Period
Revenue and gross profit for the three and six months ended June 30, 2025, are lower than the comparable periods in 2024 due to:
- Geopolitical Conflict: The conflict between Israel and Iran caused delayed shipments and lower sales.
- Loss of Specific Revenue: Absence of $100,000 in revenue from the exclusive distribution agreement with Terumo Corporation and other services in Japan, which was recorded in the six-month period ended June 30, 2024.
Guidance, Outlook, and Risks
- Financial Outlook: Management expects a higher net loss for the six months ended June 30, 2025, driven by reduced revenue and gross profit.
- Rights Offering: On July 10, 2025, the Company announced the commencement of a Rights Offering (details in Exhibit 99.1).
- Data Reliability: The financial information is preliminary, unaudited, and based on management estimates. It is subject to final adjustments and internal review.
- Risks: Continued impact of geopolitical conflict on operations and supply chain; potential fluctuations in operating expenses.
Investor Verification Checklist
- Verify the final audited financial results for the six months ended June 30, 2025, once the Company completes its financial closing procedures.
- Review the terms and status of the Rights Offering announced on July 10, 2025.
- Monitor the ongoing impact of the Israel-Iran conflict on shipment delays and future sales volumes.
- Confirm the status of the distribution agreement with Terumo Corporation in Japan.